Clinical Trial Update: Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rituximab for idiopathic membranous nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Idiopathic Membranous Nephropathy | Phase 3 | Status: COMPLETED